HPA axis

1 stories · following the connections

Business

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder

By Nasdaq OMXDec 21, 2017, 1:00 PM UTC